Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,328 active trials222 approved drugs2,775 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,686 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06255197 | Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers | recruiting | — | 60,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06263530 | Prognostic Significance of ctDNA in HL | recruiting | — | 500 | Interni hematologicka klinika FNKVNETWORK | 1 | Feb 16, 2024 |
| clinicaltrials |
| NCT05525273 | Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma(Swecranio) | recruiting | Phase 2 | 25 | Eva Marie Erfurth, MD, PhDOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT06241807 | Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC | recruiting | Phase 2 | 30 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT06259162 | LAG3 Expression in Triple Negative Breast Cancer | recruiting | N/A | 128 | Samsung Medical CenterOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT06255210 | Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)(ESICON) | recruiting | Phase 2 | 25 | Hongmeng YuOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT06256627 | The Maintenance Treatment of "ITIVA" in AML Patients | recruiting | N/A | 130 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05199376 | Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neurofibromatosis Type 1(CryoNF1) | recruiting | N/A | 30 | Centre Leon BerardOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT06230549 | Adaptive Radiotherapy in Patients With Gynecological Tumors(ProART) | recruiting | N/A | 30 | University Hospital, EssenOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT06250595 | European Rare Blood Disorders Platform (ENROL)(ENROL) | recruiting | — | 37,090 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06182657 | The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC | recruiting | — | 300 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06247605 | A Phase IIII Study of AL8326 in Small Cell Lung Cancer | recruiting | Phase 3 | 243 | Advenchen Laboratories Nanjing Ltd.INDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06249750 | Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer | recruiting | Phase 2 | 60 | Pengyuan LiuOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05192655 | Artificial Intelligence in Functional Imaging for Individualized Treatment of Head and Neck Squamous Cell Carcinoma Patients(KIVAL-KHT) | recruiting | — | 250 | Charite University, Berlin, GermanyOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05678270 | A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 70 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05794048 | METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors(PROMETHEP) | recruiting | N/A | 300 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06236568 | Impact of Graft Reconditioning With Hypothermic Machine Perfusion on HCC Recurrence After Liver Transplantation | recruiting | N/A | 40 | Azienda Ospedaliero-Universitaria di ModenaOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06243003 | WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases | recruiting | Phase 1 / Phase 2 | 56 | Fudan UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06246162 | Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05760378 | Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. | recruiting | Phase 3 | 223 | Fudan UniversityOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06244225 | HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 38 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06240689 | A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood | recruiting | Phase 2 | 104 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT06241599 | A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) | recruiting | Phase 2 / Phase 3 | 300 | Sun Yat-sen UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT05952947 | HRYZ-T101 Injection for HPV18 Positive Solid Tumor | recruiting | Phase 1 | 32 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06001281 | Predictive Value of Soluble CD146 in Glioblastoma Patients(MUCIGLIO-01) | recruiting | N/A | 55 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06237192 | MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients | recruiting | N/A | 200 | National Research Center for Hematology, RussiaNETWORK | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05243212 | Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 75 | Sheba Medical CenterOTHER_GOV | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05695638 | Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment | recruiting | — | 3,000 | Morten LadekarlOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05731622 | Effect of a SI-MMC on the IVR Rate After Ureteroscopy for UTUC(SINCERE) | recruiting | — | 100 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06225856 | An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies | recruiting | Phase 1 | 96 | Shanghai Yuyao Biotech Co., Ltd.INDUSTRY | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06232694 | Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML | recruiting | N/A | 54 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05060783 | Renal Cancer Detection With Liquid Biopsy(GaGnostic) | recruiting | — | 200 | Zealand University HospitalOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT05379738 | Impact of Adapted Physical Activity on Patient's Recovery Following Allogeneic Stem Cell Transplantation for Hematological Malignancy(APALLO) | recruiting | N/A | 75 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT05382728 | Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) | recruiting | Phase 3 | 680 | TYK Medicines, IncINDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT05962892 | A Study of Factors Influencing Recurrence After Thermal Ablation of Papillary Thyroid Carcinoma | recruiting | — | 600 | Beijing Friendship HospitalOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06190067 | Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma | recruiting | Phase 2 | 40 | Navy General Hospital, BeijingOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06220617 | Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC) | recruiting | — | 3,600 | Zhejiang UniversityOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06229340 | Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations(NТО-RAS) | recruiting | Phase 2 | 20 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Jan 29, 2024 | clinicaltrials |
| NCT05746897 | A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 38 | Hefei TG ImmunoPharma Co., Ltd.OTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT06098547 | LIver Transplantation for Non-Resectable Intrahepatic CholAngiocarcinoma (LIRICA)(LIRICA) | recruiting | N/A | 10 | Azienda Sanitaria OspedalieraOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06220487 | A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL(ABC) | recruiting | Phase 2 | 67 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06220552 | The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma | recruiting | Phase 2 | 20 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT05446155 | BioMEL- Diagnostic and Prognostic Factors in Melanoma.(BioMEL) | recruiting | — | 2,000 | Region SkaneOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06218810 | Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer | recruiting | Phase 2 | 53 | Fudan UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06219096 | Application of ICG@HSA Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection | recruiting | N/A | 100 | West China HospitalOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05969041 | Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors(MYE Symphony) | recruiting | Phase 1 | 48 | Myeloid TherapeuticsINDUSTRY | 1 | Jan 18, 2024 | clinicaltrials |
| NCT06211166 | Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction | recruiting | — | 300 | Peking University People's HospitalOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT06211790 | Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma | recruiting | Phase 2 | 66 | Fudan UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT01281735 | International Chronic Myeloid Leukemia Pediatric Study(ICMLPed) | recruiting | — | 750 | Poitiers University HospitalOTHER | 20 | Jan 17, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Feb 16, 2024source: clinicaltrials